fda semaglutide compounding enforcement october 2025 Compounded "semaglutide" is not FDA-approved New Study Finds Compounded GLP-1s

10.1016/j.pharmthera.2021.107936 140 RichardsonR

Mezydlo, A

Its gone through the usual channels from pharmacy to Medicare Advantage to (at this point) nowhere

The ADA/EASD consensus report 4 highlights the use of DDP-4 inhibitors when intermediate efficacy for glucose lowering is required and where weight management goals would prefer a weight-neutral approach

HIF1 overexpression, oncogene activation (cMyc, K-ras- mTORC1, and Akt), activation of signaling pathways (PI3K/Akt/mTORC1, Ras/Raf/MEK/ERK), an increase in glucose (GLUT) and lactate (MCT4) transporters, and the activation of glycolytic enzymes (HK2, PFK1, ENO1, PKM2, and LDHA) (Wallace, 2005